IDH2 and acute myeloid leukemia: In addition, autologous HCT consolidation will need to be challenged by other options including maintenance strategies with hypomethylating agents or with compounds specifically targeting molecular abnormalities such as FLT3, or, more recently, IDH1 and IDH2. However, maintenance treatment with targeted compounds and/or with hypomethylating agents following autologous HCT may also represent promising strategies to be studied to further improve the outcome of older AML patients after HCT.